Cobra Biologics Ltd. and Novolytics have achieved a milestone in the development of two Staphylococcus aureus based phage products for Phase I trials with a 100 fold increase in upstream process yields. An existing process was transferred to Cobra’s phage team for further process development in order to increase yields for the two Staphylococcus aureus based phage products. The controlled, high yield process provides Novolytics with a path forward to producing suitable GMP material for human cli...